52 completed, 46 recruiting, 28 active not recruiting, 16 terminated. 72 Phase 2, 43 Phase 1, 20 Not applicable, 18 Phase 3, 6 Early Phase 1.
Follow Metastatic Prostate Cancer: new trials by email Literature Review of Metastatic Prostate Cancer trials Research Report on Metastatic Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy 177Lu-PSMA-I&T - escalating renal absorbed dose, 177Lu-PSMA-I&T - recommended phase 2 regime - Cancer, Prostate Cancer | Phase 1 / Phase 2 | Not yet recruiting | CHU de Quebec-Universite Laval | 500 | 2028-03-01 | 2025-03-30 |
| Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer Sipuleucel-T, N803 - Prostate Cancer, Metastatic Prostate Cancer | Phase 1 | Not yet recruiting | Washington University School of Medicine | 30 | 2026-11-30 | 2026-08-10 |
| [18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC) 1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one, FTT-PET/CT, EnhanceAR-Seq - Metastatic Prostate Cancer, Prostate Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 75 | 2026-11-01 | 2026-10-21 |
| Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer Bicalutamide, Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography, 18F-rhPSMA-7.3 - Prostate Cancer, Recurrent Prostate Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 20 | 2026-10-31 | 2026-09-11 |
| Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery Drug: 68-Ga PSMA11, Adaptive stereotactic ablative radiotherapy (SABR), 68Ga-PSMA-11 - Prostate Cancer, Castration Sensitive Prostate Cancer | Early Phase 1 | Not yet recruiting | University of Texas Southwestern Medical Center | 30 | 2026-10-01 | 2026-08-24 |
| Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC JANX013, JANX007 - Prostate Cancer, Castration-Resistant Prostate Cancer (CRPC) | Phase 1 | Recruiting | Janux Therapeutics | 110 | 2026-09-10 | 2026-09-17 |
| A Study Testing if Patients With Advanced Prostate Cancer Who Are Responding Well to Combination Treatment Can Safely Reduce Their Medication to a Single Hormone Therapy, Compared to Continuing Their Current Drugs De-escalation strategy, Continuation of initial Androgen Deprivation Therapy (ADT) and Androgen Receptor Pathway Inhibitor (ARPI) combination therapy at standard doses - Castration Sensitive Prostate Cancer, Metastatic Prostate Cancer | Phase 2 | Not yet recruiting | Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute | 170 | 2026-09-01 | 2026-10-07 |
| AI-Assisted Patient Support in mHSPC The Same Platform without AI Agent, AI Agent-Assisted Patient-Centered Support, Delayed AI Agent-Assisted Patient-Centered Support - Metastatic Prostate Cancer | Not applicable | Not yet recruiting | Fudan University | 160 | 2026-09-01 | 2026-09-04 |
| Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT) Naltrexone - Metastatic Prostate Cancer | Phase 2 | Recruiting | University of Arkansas | 60 | 2026-08-25 | 2026-09-08 |
| Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial Abiraterone Acetate, Biospecimen Collection, Leuprolide Acetate - Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Mayo Clinic | 202 | 2026-08-04 | 2026-09-18 |
| PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan Metastatic Prostate Cancer | Not yet recruiting | Novartis Pharmaceuticals | 753 | 2026-08-01 | 2026-03-20 | |
| PSMA PET-Staged Comprehensive Progression-Directed Radiotherapy for Limited Progression in Prostate Cancer Comprehensive Progression-Directed Radiotherapy - Oligoprogressive Prostate Cancer, Metastatic Prostate Cancer | Recruiting | Affidea Nu-med Center of Oncological DIagnostics and Therapy | 1000 | 2026-06-26 | 2026-09-17 | |
| Prostate Radiotherapy and Metastasis-Directed Therapy in Synchronous Oligometastatic Prostate Cancer Definitive Prostate-Directed Radiotherapy, Metastasis-Directed Stereotactic Body Radiotherapy, Pelvic Lymph Node Irradiation - Prostate Cancer, Metastatic Prostate Cancer | Recruiting | Affidea Nu-med Center of Oncological DIagnostics and Therapy | 700 | 2026-06-26 | 2026-07-06 | |
| Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer AZD2265 (FPI-2265), Palacaparib (AZD9574), Docetaxel - Metastatic Prostate Cancer | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 152 | 2026-06-03 | 2026-10-14 |
| Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer Dapagliflozin (10mg Tab), standard medical care (ADT + NHA) - Prostate Cancer, Metastatic Prostate Cancer | Phase 2 | Not yet recruiting | Yung NA | 60 | 2026-06-01 | 2025-12-30 |
| First-in-human Diagnostic Imaging Profile of the Theranostic Pair [68Ga]Ga-DOTA-STR-17126 and Low Dose [177Lu] Lu-DOTA-STR-17126 in Patients With Advanced or Metastatic Cancer [177Lu]Lu-DOTA-STR-17126, [68Ga]Ga-DOTA-STR-17126 - Metastatic Breast Cancer, Metastatic Prostate Cancer | Early Phase 1 | Recruiting | Integrated Haematology and Oncology Network | 20 | 2026-05-28 | 2026-06-10 |
| First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer AZD8359 - Metastatic Prostate Cancer | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 42 | 2026-05-18 | 2026-10-09 |
| PROMET-BR - Molecular Profiling of Metastatic Prostate Cancer: a Brazilian Cohort Archived FFPE tissue biopsy and/or newly acquired liquid biopsy for molecular profiling. - Metastatic Prostate Cancer | Not yet recruiting | AstraZeneca | 100 | 2026-04-30 | 2026-05-01 | |
| A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer GDC-1261 - Advanced Prostate Cancer, Metastatic Prostate Cancer | Phase 1 / Phase 2 | Recruiting | Genentech, Inc. | 260 | 2026-04-29 | 2026-10-06 |
| ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium Actinium (225Ac) rhPSMA-10.1 - Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer | Phase 1 / Phase 2 | Recruiting | University College, London | 60 | 2026-04-13 | 2026-05-08 |
Showing 20 of 175. Sign in to see all of them.
Prostatic Neoplasms (175) · Breast Neoplasms (14) · Neoplasm Metastasis (10) · Neoplasms (9) · Lung Neoplasms (5) · Motor Activity (4) · Pancreatic Neoplasms (4) · Genital Diseases, Male (3) · Genital Neoplasms, Male (3) · Melanoma (3) · Ovarian Neoplasms (3) · Prostatic Diseases (3) · Urogenital Neoplasms (3) · Adenocarcinoma (2) · Anxiety Disorders (2)
Genital Diseases (175) · Urogenital Diseases (175) · Male Urogenital Diseases (173) · Neoplasms by Site (173) · Genital Diseases, Male (172) · Genital Neoplasms, Male (172) · Prostatic Diseases (172) · Urogenital Neoplasms (172) · Neoplasms (166) · Pathological Conditions, Signs and Symptoms (16) · Breast Diseases (14) · Pathologic Processes (14) · Skin Diseases (14) · Skin and Connective Tissue Diseases (14) · Neoplastic Processes (12)
Docetaxel (16) · Prednisone (16) · enzalutamide (13) · Abiraterone Acetate (12) · abiraterone (10) · darolutamide (8) · Androgen Antagonists (7) · Pluvicto (6) · apalutamide (6) · cabazitaxel (6) · 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid (5) · Blood Specimen Collection (4) · Carboplatin (4) · Goserelin (4) · Leuprolide (4)
AstraZeneca (7) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (7) · University Health Network, Toronto (5) · Dana-Farber Cancer Institute (4) · Fudan University (4) · Memorial Sloan Kettering Cancer Center (4) · National Cancer Institute (NCI) (4) · University of California, San Francisco (4) · Janssen Research & Development, LLC (3) · Sun Yat-sen University (3) · Tampere University Hospital (3) · The First Affiliated Hospital with Nanjing Medical University (3) · Washington University School of Medicine (3) · Affidea Nu-med Center of Oncological DIagnostics and Therapy (2) · Astellas Pharma Global Development, Inc. (2)
United States (88) · United Kingdom (23) · China (20) · Canada (19) · Australia (18) · Spain (18) · France (17) · Italy (12) · South Korea (8) · Brazil (7) · Germany (7) · Netherlands (7) · Poland (7) · Belgium (6) · Taiwan (6)
Daniel Kwon, MD (2) · Heather Jacene, MD (2) · Jing-Ren Tseng, MD (2) · Lixxin Hua (2) · Peter L Choyke, M.D. (2) · Shabbir Alibhai, MD (2) · Tamim Niazi, MD (2) · Abhishek Solanki, MD MS (1) · Abi Vainstein-Haras, MD (1) · Adriana Coletta, PhD, MS, RD (1) · Albert Font, MD (1)
PMID 21976132, PMID 24126237, PMID 29240541, PMID 29764892, PMID 30686756, PMID 33270906, PMID 33541288, PMID 33568190, PMID 33632752, PMID 34246347, PMID 35034502, PMID 35405085, PMID 35487730, PMID 35963650, PMID 36099670, PMID 36305957, PMID 36697317, PMID 37058234, PMID 38167882, PMID 38197680, PMID 38521641, PMID 38637770, PMID 38796422, PMID 38951803, PMID 38979716, PMID 39172730, PMID 39569542, PMID 39632499, PMID 39737899, PMID 39923274, PMID 39924002, PMID 40523369, PMID 41210271, PMID 42115448, PMID 42141175, PMID 42252348, PMID 42875559
2019 (3), 2023 (3), 2016 (2), 2014 (1), 2025 (1), I01CX002277 (1), P50CA103175 (1), P50CA272390 (1), R01CA223484 (1), R01CA281759 (1), R01CA306993 (1), R44CA250824 (1), U01CA183031 (1)